Compare · CRL vs NRC
CRL vs NRC
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and NRC Health (NRC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and NRC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.21B, about 29.2x NRC ($487.1M).
- Over the past year, CRL is up 81.7% and NRC is up 43.2% - CRL leads by 38.6 points.
- CRL has been more active in the news (17 items in the past 4 weeks vs 2 for NRC).
- CRL has more recent analyst coverage (25 ratings vs 1 for NRC).
- Company
- Charles River Laboratories International Inc.
- NRC Health
- Price
- $297.55-0.34%
- $22.07+0.62%
- Market cap
- $14.21B
- $487.1M
- 1M return
- +32.71%
- +3.88%
- 1Y return
- +81.73%
- +43.16%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 17
- 2
- Recent ratings
- 25
- 1
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Latest CRL
- Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)
- Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- Chief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.
- EVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)
- Director Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)
Latest NRC
- NRC Health filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by NRC Health
- New NRC Health Research Reveals What Drives Patient Loyalty Beyond Access
- NRC Health filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NRC Health Announces Second Quarter 2026 Results
- NRC Health filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Berwick Donald M was granted 7,697 shares (SEC Form 4)
- Director Bhandari Parul was granted 7,697 shares (SEC Form 4)
- Director Lockhart Stephen H was granted 7,697 shares (SEC Form 4)
- Director Nunnelly John N was granted 7,697 shares, increasing direct ownership by 24% to 40,363 units (SEC Form 4)